Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
PARSIPPANY, N.J., Feb. 15, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Pacira Pharmaceuticals management team is scheduled to participate in an analyst-led fireside chat at the 2017 RBC Capital Markets’ Healthcare Conference at 10:00 a.m. ET on Wednesday, February 22, 2017, in New York.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 [email protected]
